{
    "info": {
        "nct_id": "NCT03747042",
        "official_title": "Pre-Surgical Trial of Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer",
        "inclusion_criteria": "1. Eligibility waivers are not permitted. Subjects must meet all of the inclusion and exclusion criteria to be registered to the study. Study treatment may not begin until a subject is registered.\n2. Patients must provide informed written consent\n3. ECOG performance status 0-2.\n4. Clinical stage operable I, II or III invasive mammary carcinoma, which is ER-positive by IHC and HER2-negative by Herceptest (0 or 1+) or not amplified by in situ hybridization as per routine clinical testing.\n\n   * Patients who have measurable residual tumor at the primary site\n   * Patients who will undergo surgical treatment with either segmental resection or total mastectomy\n5. Measurable tumor. Measurable disease: a mass that can be reproducibly measured by physical exam, mammogram or ultrasound and is at least 1 cm in size\n6. Post-menopausal female subjects ≥18 years of age, as defined by any of the following:\n\n   * Subjects at least 55 years of age;\n   * Subjects under 55 years of age and amenorrhoeic for at least 12 months or follicle-stimulating hormone (FSH) values ≥40 IU/L and estradiol levels ≤40 pg/mL (140 pmol/L) or in postmenopausal ranges per local or institutional reference ranges;\n   * Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months.\n   * (There is no upper age limit for enrollment to this study)\n7. No prior chemotherapy for this primary breast cancer.\n8. Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer.\n9. Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least 14 days prior to study enrollment.\n10. Subjects must have ended hormone replacement therapy (HRT) (e.g., conjugated estrogens tablets, USP, [Premarin]), at least 7 days prior to receiving the first dose of randomized therapy.\n11. Patients must have adequate hepatic and renal function. All tests must be obtained less than 4 weeks from study entry. This includes:\n\n    1. Creatinine <2X upper limits of normal\n    2. Bilirubin, SGOT, SGPT <1.5X upper limits of normal\n12. Able to swallow and retain oral medication\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Patients with locally advanced disease who are candidates for other preoperative chemotherapy at the time of initial evaluation. This may include patients with locally advanced disease such as:\n\n   * Inflammatory breast cancer (T4d)\n   * Fixed axillary lymph node metastases (N2)\n   * Metastasis to ipsilateral internal mammary node (N3)\n2. Locally recurrent breast cancer\n3. Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.)\n4. Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality.\n5. Severe uncontrolled malabsorption condition or disease (i.e. grade II/III diarrhea, severe malnutrition, short gut syndrome)\n6. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n7. Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of letrozole.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Eligibility waivers are not permitted. Subjects must meet all of the inclusion and exclusion criteria to be registered to the study. Study treatment may not begin until a subject is registered.",
            "criterions": [
                {
                    "exact_snippets": "Subjects must meet all of the inclusion and exclusion criteria to be registered to the study.",
                    "criterion": "inclusion and exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Study treatment may not begin until a subject is registered.",
                    "criterion": "registration status",
                    "requirements": [
                        {
                            "requirement_type": "registration before treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Clinical stage operable I, II or III invasive mammary carcinoma, which is ER-positive by IHC and HER2-negative by Herceptest (0 or 1+) or not amplified by in situ hybridization as per routine clinical testing.",
            "criterions": [
                {
                    "exact_snippets": "Clinical stage operable I, II or III invasive mammary carcinoma",
                    "criterion": "clinical stage of invasive mammary carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "I",
                                "II",
                                "III"
                            ]
                        },
                        {
                            "requirement_type": "operability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ER-positive by IHC",
                    "criterion": "estrogen receptor (ER) status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "IHC"
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2-negative by Herceptest (0 or 1+) or not amplified by in situ hybridization",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "negativity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": [
                                "Herceptest (0 or 1+)",
                                "not amplified by in situ hybridization"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Subjects must have ended hormone replacement therapy (HRT) (e.g., conjugated estrogens tablets, USP, [Premarin]), at least 7 days prior to receiving the first dose of randomized therapy.",
            "criterions": [
                {
                    "exact_snippets": "Subjects must have ended hormone replacement therapy (HRT) ... at least 7 days prior to receiving the first dose of randomized therapy.",
                    "criterion": "hormone replacement therapy (HRT)",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_time_before_randomized_therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have measurable residual tumor at the primary site",
            "criterions": [
                {
                    "exact_snippets": "measurable residual tumor at the primary site",
                    "criterion": "residual tumor at the primary site",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects at least 55 years of age;",
            "criterions": [
                {
                    "exact_snippets": "at least 55 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Prior bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior radiation castration with amenorrhea for at least 6 months",
                    "criterion": "radiation castration with amenorrhea",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of amenorrhea",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who will undergo surgical treatment with either segmental resection or total mastectomy",
            "criterions": [
                {
                    "exact_snippets": "Patients who will undergo surgical treatment with either segmental resection or total mastectomy",
                    "criterion": "planned surgical treatment",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "segmental resection",
                                "total mastectomy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (There is no upper age limit for enrollment to this study)",
            "criterions": [
                {
                    "exact_snippets": "There is no upper age limit for enrollment to this study",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "upper limit",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients must provide informed written consent",
            "criterions": [
                {
                    "exact_snippets": "Patients must provide informed written consent",
                    "criterion": "informed written consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "prior history of contralateral breast cancer",
                    "criterion": "prior history of contralateral breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of recurrence of their initial primary breast cancer",
                    "criterion": "recurrence of initial primary breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "evidence of recurrence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Bilirubin, SGOT, SGPT <1.5X upper limits of normal",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ... <1.5X upper limits of normal",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "SGOT ... <1.5X upper limits of normal",
                    "criterion": "SGOT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "SGPT <1.5X upper limits of normal",
                    "criterion": "SGPT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Measurable tumor. Measurable disease: a mass that can be reproducibly measured by physical exam, mammogram or ultrasound and is at least 1 cm in size",
            "criterions": [
                {
                    "exact_snippets": "Measurable tumor",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Measurable disease: a mass that can be reproducibly measured by physical exam, mammogram or ultrasound and is at least 1 cm in size",
                    "criterion": "disease mass",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "physical exam",
                                "mammogram",
                                "ultrasound"
                            ]
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects under 55 years of age and amenorrhoeic for at least 12 months or follicle-stimulating hormone (FSH) values ≥40 IU/L and estradiol levels ≤40 pg/mL (140 pmol/L) or in postmenopausal ranges per local or institutional reference ranges;",
            "criterions": [
                {
                    "exact_snippets": "Subjects under 55 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<",
                                "value": 55,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "amenorrhoeic for at least 12 months",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "follicle-stimulating hormone (FSH) values ≥40 IU/L",
                    "criterion": "FSH level",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "IU/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estradiol levels ≤40 pg/mL (140 pmol/L)",
                    "criterion": "estradiol level",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 40,
                                "unit": "pg/mL"
                            }
                        },
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 140,
                                "unit": "pmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in postmenopausal ranges per local or institutional reference ranges",
                    "criterion": "postmenopausal hormone levels",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal ranges per local or institutional reference ranges"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Creatinine <2X upper limits of normal",
            "criterions": [
                {
                    "exact_snippets": "Creatinine <2X upper limits of normal",
                    "criterion": "creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "times upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Able to swallow and retain oral medication",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow and retain oral medication",
                    "criterion": "ability to swallow oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to swallow and retain oral medication",
                    "criterion": "ability to retain oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Post-menopausal female subjects ≥18 years of age, as defined by any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Post-menopausal female subjects",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    ]
                },
                {
                    "exact_snippets": "female subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. No prior chemotherapy for this primary breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "No prior chemotherapy for this primary breast cancer",
                    "criterion": "prior chemotherapy for primary breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Patients must have adequate hepatic and renal function. All tests must be obtained less than 4 weeks from study entry. This includes:",
            "criterions": [
                {
                    "exact_snippets": "adequate hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "All tests must be obtained less than 4 weeks from study entry",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time from study entry",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least 14 days prior to study enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry",
                    "criterion": "prior use of tamoxifen or raloxifene",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have discontinued the drug for at least 14 days prior to study enrollment",
                    "criterion": "discontinuation period of tamoxifen or raloxifene",
                    "requirements": [
                        {
                            "requirement_type": "minimum discontinuation period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. ECOG performance status 0-2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "5. Severe uncontrolled malabsorption condition or disease (i.e. grade II/III diarrhea, severe malnutrition, short gut syndrome)",
            "criterions": [
                {
                    "exact_snippets": "Severe uncontrolled malabsorption condition or disease",
                    "criterion": "malabsorption condition or disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "grade II/III diarrhea",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "II",
                                "III"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "severe malnutrition",
                    "criterion": "malnutrition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "short gut syndrome",
                    "criterion": "short gut syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Dementia",
                    "criterion": "dementia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "altered mental status",
                    "criterion": "altered mental status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any psychiatric condition that would prohibit the understanding or rendering of informed consent",
                    "criterion": "psychiatric condition prohibiting informed consent",
                    "requirements": [
                        {
                            "requirement_type": "impact on informed consent",
                            "expected_value": "prohibits understanding or rendering of informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients with locally advanced disease who are candidates for other preoperative chemotherapy at the time of initial evaluation. This may include patients with locally advanced disease such as:",
            "criterions": [
                {
                    "exact_snippets": "Patients with locally advanced disease",
                    "criterion": "locally advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "candidates for other preoperative chemotherapy at the time of initial evaluation",
                    "criterion": "candidate for other preoperative chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of initial evaluation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastasis to ipsilateral internal mammary node (N3)",
            "criterions": [
                {
                    "exact_snippets": "Metastasis to ipsilateral internal mammary node (N3)",
                    "criterion": "metastasis to ipsilateral internal mammary node",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality.",
            "criterions": [
                {
                    "exact_snippets": "Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality",
                    "criterion": "serious medical illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk of operative mortality",
                            "expected_value": "high (in the judgment of the treating physician)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of letrozole.",
            "criterions": [
                {
                    "exact_snippets": "Use of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of letrozole.",
                    "criterion": "use of investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inflammatory breast cancer (T4d)",
            "criterions": [
                {
                    "exact_snippets": "Inflammatory breast cancer (T4d)",
                    "criterion": "inflammatory breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Locally recurrent breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Locally recurrent breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "recurrence location",
                            "expected_value": "local"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fixed axillary lymph node metastases (N2)",
            "criterions": [
                {
                    "exact_snippets": "Fixed axillary lymph node metastases (N2)",
                    "criterion": "axillary lymph node metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "fixation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "nodal stage",
                            "expected_value": "N2"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.)",
                    "criterion": "distant metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}